{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:28:18Z","timestamp":1770139698751,"version":"3.49.0"},"reference-count":63,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:p>Psoriasis is a common skin disorder affecting approximately 1% of the general population. The treatment of psoriasis depends on the body surface area involvement, quality of life impairment and associated co-morbidities.  Special population comprising of pregnant women, lactating mothers, elderly individuals and children, is more vulnerable. They are not included in drug trials; rendering the data for use of systemic treatment scant and is mainly based on anecdotal evidence. In this narrative review, we discuss systemic treatment options in this special population. Though couples planning a family are not considered a special population, they form a subset that require special therapeutic consideration and have also been included in this review.<\/jats:p>","DOI":"10.25259\/ijdvl_7_2023","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T06:57:02Z","timestamp":1684479422000},"page":"170-177","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Systemic treatment of psoriasis in special population"],"prefix":"10.25259","volume":"90","author":[{"given":"Shekhar","family":"Neema","sequence":"first","affiliation":[{"name":"Department of Dermatology, AFMC, Pune, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Kothari","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Command Hospital Air Force, Bengaluru, Karnataka, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aradhana","family":"Rout","sequence":"additional","affiliation":[{"name":"Department of Dermatology, MH Jammu, J&K, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth","family":"Mani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, INHS Sanjivani Kochi, Kerala, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, INHS Asvini, Mumbai, Maharashtra, India,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunmeet","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, 7AFH Kanpur, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"key":"10.25259\/IJDVL_7_2023\/ref-1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/s0190-9622(85)70188-0","article-title":"Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris","volume":"13","author":"Henseler","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4103\/0378-6323.72443","article-title":"Psoriasis in India: prevalence and pattern","volume":"76","author":"Dogra","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_7_2023\/ref-3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3109\/10601333.2015.1001900","article-title":"Special population considerations and regulatory affairs for clinical research","volume":"32","author":"Grimsrud","year":"2015","journal-title":"Clin Res Regul Aff"},{"key":"10.25259\/IJDVL_7_2023\/ref-4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1684\/ejd.2016.2932","article-title":"Childhood psoriasis","volume":"26","author":"Mah\u00e9","year":"2016","journal-title":"European J Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1046\/j.1525-1470.2001.018003188.x","article-title":"Childhood psoriasis: A clinical review of 1262 cases","volume":"18","author":"Morris","year":"2001","journal-title":"Pediatr Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/pde.13028","article-title":"Nail psoriasis: a systematic evaluation in 313 children with psoriasis","volume":"34","author":"Pourchot","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-7","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/1346-8138.13713","article-title":"Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: A multicenter, cohort study","volume":"44","author":"Ergun","year":"2017","journal-title":"J Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1046\/j.1525-1470.2001.018003246.x","article-title":"Low dose cyclosporin A treatment in generalized pustular psoriasis","volume":"18","author":"Kilic","year":"2001","journal-title":"Pediatr Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1525-1470.2009.00918.x","article-title":"Generalized pustular psoriasis in a 6-week-old infant","volume":"26","author":"Chao","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-10","volume-title":"Soriatane (acitretin) capsules [package insert]","year":"2017"},{"key":"10.25259\/IJDVL_7_2023\/ref-11","volume-title":"Absorica (isotretinoin) [package insert]","year":"2018"},{"key":"10.25259\/IJDVL_7_2023\/ref-12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jaad.2019.08.019","article-title":"Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study","volume":"82","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000503062","article-title":"Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and Efficacy in Children","volume":"236","author":"AlMutairi","year":"2020","journal-title":"Dermatology"},{"key":"10.25259\/IJDVL_7_2023\/ref-14","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jaad.2010.04.004","article-title":"Long-term etanercept in pediatric patients with plaque psoriasis","volume":"63","author":"Paller","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_7_2023\/ref-16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/pde.13767","article-title":"Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis","volume":"36","author":"Wells","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-17","first-page":"1","article-title":"The evolving role of biologics in the treatment of pediatric psoriasis","volume":"18","author":"Luu","year":"2013","journal-title":"Skin Therapy Lett"},{"key":"10.25259\/IJDVL_7_2023\/ref-18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/archderm.141.5.601","article-title":"Hormonal effect on psoriasis in pregnancy and postpartum","volume":"141","author":"Murase","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bjd.14547","article-title":"Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies","volume":"175","author":"Bobotsis","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-20","first-page":"183","article-title":"Pregnancy outcome in women with psoriasis","volume":"53","author":"Ben-David","year":"2008","journal-title":"medicine Reprod Med"},{"key":"10.25259\/IJDVL_7_2023\/ref-21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/14740338.2020.1744562","article-title":"An update on the safety of apremilast for the treatment of plaque psoriasis","volume":"19","author":"Shavit","year":"2020 Apr","journal-title":"Expert Opin Drug Saf"},{"key":"10.25259\/IJDVL_7_2023\/ref-22","doi-asserted-by":"publisher","first-page":"401.e1","DOI":"10.1016\/j.jaad.2013.09.010","article-title":"Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy","volume":"70","author":"Murase","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/IJWH.S125784","article-title":"Pustular psoriasis of pregnancy: current perspectives","volume":"10","author":"Trivedi","year":"2018","journal-title":"Int J Womens Health"},{"key":"10.25259\/IJDVL_7_2023\/ref-24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2230.2008.02963.x","article-title":"Generalized pustular psoriasis of pregnancy treated with infliximab","volume":"34","author":"Sheth","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-25","doi-asserted-by":"publisher","first-page":"e13040","DOI":"10.1111\/dth.13040","article-title":"Impetigo herpetiformis responsive to secukinumab","volume":"32","author":"Chhabra","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_7_2023\/ref-26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijwd.2016.12.003","article-title":"Update on biologic safety for patients with psoriasis during pregnancy","volume":"3","author":"Porter","year":"2017","journal-title":"Int J Womens Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-27","first-page":"1","article-title":"Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy","volume":"26","author":"Strain","year":"2021 Mar","journal-title":"Skin Therapy Lett"},{"key":"10.25259\/IJDVL_7_2023\/ref-28","article-title":"Methotrexate","year":"2006","journal-title":"Drugs and Lactation Database (LactMed) [Internet]"},{"key":"10.25259\/IJDVL_7_2023\/ref-29","article-title":"Cyclosporine","year":"2006","journal-title":"Drugs and Lactation Database (LactMed) [Internet]"},{"key":"10.25259\/IJDVL_7_2023\/ref-30","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1080\/09546634.2018.1544413","article-title":"Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis","volume":"30","author":"Plachouri","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_7_2023\/ref-31","doi-asserted-by":"publisher","first-page":"821","DOI":"10.5114\/ada.2020.102089","article-title":"The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines","volume":"37","author":"Owczarek","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"10.25259\/IJDVL_7_2023\/ref-32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-4632.2011.04979.x","article-title":"Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype?","volume":"51","author":"Kwon","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1742-4933-6-10","article-title":"Mechanisms of immunosenescence","volume":"22","author":"Caruso","year":"2009","journal-title":"Immun Ageing"},{"key":"10.25259\/IJDVL_7_2023\/ref-34","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/14712598.2018.1504016","article-title":"An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly","volume":"18","author":"Di Lernia","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.25259\/IJDVL_7_2023\/ref-35","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1468-3083.2010.03836.x","article-title":"Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients","volume":"25","author":"Sanchez-Moya","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_7_2023\/ref-36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2340\/00015555-1719","article-title":"Efficacy and safety of systemic treatments for psoriasis in elderly patients","volume":"94","author":"Piaserico","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.25259\/IJDVL_7_2023\/ref-37","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1136\/bmj.298.6676.801","article-title":"Methotrexate dosage in patients aged over 50 with psoriasis","volume":"298","author":"Fairris","year":"1989","journal-title":"BMJ"},{"key":"10.25259\/IJDVL_7_2023\/ref-38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1468-3083.2011.03992.x","article-title":"Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in nonplaque psoriasis","volume":"25 suppl 2","author":"Maza","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_7_2023\/ref-39","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/s0190-9622(96)90726-4","article-title":"Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure","volume":"35","author":"Lowe","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-40","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.adengl.2013.01.001","article-title":"Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"104","author":"Carretero","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"10.25259\/IJDVL_7_2023\/ref-41","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2340\/00015555-1921","article-title":"Low-dose acitretin in treatment of plaque type psoriasis: descriptive study of efficacy and safety","volume":"95","author":"Borghi","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.25259\/IJDVL_7_2023\/ref-42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-43","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_7_2023\/ref-44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/cpdd.256","article-title":"Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12","volume":"5","author":"Liu","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.25259\/IJDVL_7_2023\/ref-45","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/jdv.13771","article-title":"Real-Life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single centre, retrospective study","volume":"31","author":"Chiricozzi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_7_2023\/ref-46","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2009.09.040","article-title":"Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis","volume":"63","author":"Menter","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jaad.2006.02.010","article-title":"Etanercept for the treatment of psoriasis in the elderly","volume":"55","author":"Militello","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-48","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000345623","article-title":"Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study","volume":"225","author":"Esposito","year":"2012","journal-title":"Dermatology"},{"key":"10.25259\/IJDVL_7_2023\/ref-49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40266-018-0520-z","article-title":"Efficacy and safety of Secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies","volume":"35","author":"K\u00f6rber","year":"2018","journal-title":"Drugs Aging"},{"key":"10.25259\/IJDVL_7_2023\/ref-50","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/ced.12850","article-title":"Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period","volume":"41","author":"Megna","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-51","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/1346-8138.12653","article-title":"Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis","volume":"41","author":"Hayashi","year":"2014","journal-title":"J Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-52","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1159\/000471849","article-title":"Untreated psoriasis impairs male fertility: a case-control study","volume":"233","author":"Caldarola","year":"2017","journal-title":"Dermatology"},{"key":"10.25259\/IJDVL_7_2023\/ref-53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/PTT.S159916","article-title":"Psoriasis and sexual dysfunction: links, risks, and management challenges","volume":"8","author":"Duarte","year":"2018","journal-title":"Psoriasis (Auckl)"},{"key":"10.25259\/IJDVL_7_2023\/ref-54","doi-asserted-by":"publisher","first-page":"435","DOI":"10.4103\/1008-682X.173932","article-title":"The role of estradiol in male reproductive function","volume":"18","author":"Schulster","year":"2016","journal-title":"Asian J Androl"},{"key":"10.25259\/IJDVL_7_2023\/ref-55","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000251036","article-title":"Studies on human semen in topical corticosteroid-treated and in methotrexate-treated psoriatics","volume":"154","author":"Grunnet","year":"1977","journal-title":"Dermatologica"},{"key":"10.25259\/IJDVL_7_2023\/ref-56","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/rheumatology\/ket390","article-title":"No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate: an observational cohort study","volume":"53","author":"Weber-Schoendorfer","year":"2014","journal-title":"Rheumatology"},{"key":"10.25259\/IJDVL_7_2023\/ref-57","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/ced.12850","article-title":"Spermatological investigations in patients treated with etretinate and isotretinoin","volume":"19","author":"T\u00f6r\u00f6k","year":"1987 Nov 12","journal-title":"Andrologia"},{"key":"10.25259\/IJDVL_7_2023\/ref-58","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/ajd.12641","article-title":"Psoriasis in those planning a family, pregnant or breast\u2010feeding. The Australasian Psoriasis Collaboration","volume":"59","author":"Rademaker","year":"2018","journal-title":"Australas J Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-59","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s003830050346","article-title":"Effect of cyclosporine on fertility in male rats","volume":"13","author":"Srinivas","year":"1998 Jul","journal-title":"Pediatr Surg Int"},{"key":"10.25259\/IJDVL_7_2023\/ref-60","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/s0022-5347(17)38318-0","article-title":"Male fertility in cyclosporine treated renal transplant patients","volume":"145","author":"Haberman","year":"1991","journal-title":"J Urol"},{"key":"10.25259\/IJDVL_7_2023\/ref-61","first-page":"448","article-title":"Impregnate occasion for male renal transplant recipients]","volume":"14","author":"Xu","year":"2008","journal-title":"Zhonghua Nan Ke Xue"},{"key":"10.25259\/IJDVL_7_2023\/ref-62","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/bjd.13060","article-title":"Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients","volume":"171","author":"Yiu","year":"2014","journal-title":"Br. J. Dermatol"},{"key":"10.25259\/IJDVL_7_2023\/ref-63","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.reprotox.2015.10.008","article-title":"Assessment of ixekizumab, an interleukin-17A monoclonal antibody, for potential effects on reproduction and development, including immune system function, in cynomolgus monkeys","volume":"58","author":"Clarke","year":"2015","journal-title":"Reprod Toxicol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/systemic-treatment-of-psoriasis-in-special-population\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/systemic-treatment-of-psoriasis-in-special-population\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T06:30:27Z","timestamp":1708497027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/systemic-treatment-of-psoriasis-in-special-population\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":63,"alternative-id":["10.25259\/IJDVL_7_2023"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_7_2023","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,1]]},"article-number":"170"}}